Ziopharm Oncology (ZIOP) Reports Q3 Loss of $0.14/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Financial Fact:
Research contract revenue: 1.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research contract revenue: 1.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Ziopharm Oncology (NASDAQ: ZIOP) reported Q3 EPS of ($0.14), versus ($0.06) reported last year.
For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Intel shares fall as competitor reports record results
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
